Medical glasses and syringes with Novo Nordisk logo, were displayed on the screen in the background.
Nurphoto | Nurphoto | Getty pictures
Novo Nordibi’s shares said on Monday, the next generation of the Danish pharmaceutical giant to reduce the weight of 15.7% after 68 weeks in 68 weeks in 68 weeks.
The company’s shares were lowered at 11:22 at 11:22 AM.
Novo Nordisk, which produces more popular weight loss medicines, predicts 25% for patients who have previously received the CagRisema. As a result of another late trial, the patients who helped the company’s CAGRISEMA broadcast in December, helped to reduce 22.7% in this test.
Cagrisema NODISK is investigated as a treatment for adults with overweight or obese adults, as well as a treatment for adults with type 2 diabetes. The company is currently waiting for the regulation for CAGRISEMA in the first quarter of 2026.
This broke news story is updated.
